Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intra-articular ART-I02 safety study in rheumatoid arthritis
NL-OMON43315Withdrawn
- Sponsor
- Arthrogen
- Start
- Apr 2016
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ART-I02 in rheumatoid arthritis (RA), sponsored by Arthrogen. Primary endpoints: Safety and tolerability, Concomitant medication use and 3 more. Planned start Apr 2016; status: withdrawn.
02
Drugs
ART-I02
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON43315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43315.